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Melanie M van der Klauw1,22, Melanie Waldenberger11, Markus Perola2,3,5† and Bruce HR Wolffenbuttel1,22*†Abstract
Background: Not all obese subjects have an adverse metabolic profile predisposing them to developing type 2
diabetes or cardiovascular disease. The BioSHaRE-EU Healthy Obese Project aims to gain insights into the
consequences of (healthy) obesity using data on risk factors and phenotypes across several large-scale cohort
studies. Aim of this study was to describe the prevalence of obesity, metabolic syndrome (MetS) and metabolically
healthy obesity (MHO) in ten participating studies.
Methods: Ten different cohorts in seven countries were combined, using data transformed into a harmonized
format. All participants were of European origin, with age 18–80 years. They had participated in a clinical
examination for anthropometric and blood pressure measurements. Blood samples had been drawn for analysis of
lipids and glucose. Presence of MetS was assessed in those with obesity (BMI ≥ 30 kg/m2) based on the 2001
NCEP ATP III criteria, as well as an adapted set of less strict criteria. MHO was defined as obesity, having none of the
MetS components, and no previous diagnosis of cardiovascular disease.
Results: Data for 163,517 individuals were available; 17% were obese (11,465 men and 16,612 women). The prevalence
of obesity varied from 11.6% in the Italian CHRIS cohort to 26.3% in the German KORA cohort. The age-standardized
percentage of obese subjects with MetS ranged in women from 24% in CHRIS to 65% in the Finnish Health2000 cohort,
and in men from 43% in CHRIS to 78% in the Finnish DILGOM cohort, with elevated blood pressure the most frequently
occurring factor contributing to the prevalence of the metabolic syndrome. The age-standardized prevalence of MHO
varied in women from 7% in Health2000 to 28% in NCDS, and in men from 2% in DILGOM to 19% in CHRIS. MHO was
more prevalent in women than in men, and decreased with age in both sexes.
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Conclusions: Through a rigorous harmonization process, the BioSHaRE-EU consortium was able to compare key
characteristics defining the metabolically healthy obese phenotype across ten cohort studies. There is considerable
variability in the prevalence of healthy obesity across the different European populations studied, even when unified
criteria were used to classify this phenotype.
Keywords: Harmonization, Obesity, Metabolic syndrome, Cardiovascular disease, Metabolically healthyBackground
The current obesity epidemic is one of the greatest public
health concerns of our century [1]. In Europe, obesity has
reached epidemic proportions [2]. A study assessing data
collected between 1997 and 2003 reported that the preva-
lence of obesity, defined as body mass index (BMI) ≥
30 kg/m2, varied between 6% and 20%, with higher preva-
lence in Central and Eastern European countries and
lower values in France, Italy, and some Scandinavian
countries [3]. Among U.S. adults, obesity (BMI ≥ 30)
prevalence has increased from 15% in the early 1970s to
the most recent estimate of 34% in 2009–2010 [4,5].
Similar patterns are seen in other countries and were
shown to be comparable across different age, ethnic,
educational and income groups [6]. If the observed
trends of increasing prevalence of obesity persist, by
2030 the absolute number of obese individuals could
rise to a total of 1.12 billion, accounting for 20% of the
world’s adult population [7].
Obesity is a major contributor to the global burden of
chronic diseases and disabilities [1]. Increased adiposity is
a key risk factor for type 2 diabetes, dyslipidaemia and car-
diovascular disease, and is associated with many other
conditions, including osteoarthritis, certain types of can-
cer, mental health, and increased mortality [8-13]. How-
ever, recent evidence indicates that obesity does not
always lead to adverse metabolic effects such as impaired
glucose tolerance, insulin resistance, dyslipidaemia and
hypertension [14], a cluster of the obesity-driven alterations
also known as the metabolic syndrome (MetS) [15,16]. A
subgroup of approximately 10-30% of obese individuals is
metabolically healthy despite having excessive accumulation
of body fat [17-22]. This phenomenon is referred to in the
current literature as metabolically healthy obesity (MHO)
[23]. However, to date, little is known about the factors that
delay onset of or protect obese individuals from developing
metabolic disturbances [24].
Accumulating evidence indicates that the prevalence of
MHO varies considerably based on the set of criteria used
for its classification as well as on the cut-off values for
each parameter included [19,24,25]. In addition, other fac-
tors such as lifestyle, ethnicity, sex, or age can largely in-
fluence the prevalence of MHO [19]. Recent observational
studies show that the MHO phenotype is associated withlower risk of CVD [26] and mortality, especially in those
physically active [27], although not all studies could con-
firm these findings [28]. This highlights the importance of
investigating MHO using harmonized classification cri-
teria and studying the extent to which MHO is associated
with the risk for chronic diseases.
The BioSHaRE-EU Project is an international collabora-
tive project between European and Canadian Institutes and
European cohort studies. It aims to harmonize data from
clinical examinations and analytical results from biospeci-
mens, as well as measures of life style, social circumstances
and environmental exposures. Computing infrastructure is
developed enabling the effective pooling of data and re-
search into critical sub-components of the phenotypes as-
sociated with common complex diseases (www.bioshare.eu)
[29-31]. The Healthy Obese Project (HOP) is the first scien-
tific project in BioSHaRE to use these tools in order to gain
insights into the characterization, the determinants and
consequences of (healthy) obesity. We report the results of
the first phase of the HOP project, in which we jointly ana-
lysed data from 163,517 individuals in ten population-based
cohort studies across Europe. The objectives were to assess
the potential for harmonization and collaboration, and to
evaluate the prevalence of MetS in obese participants using
different classification criteria and by characterizing the
clinical and metabolic factors associated with MHO.
Methods
Study participants
This study included participants from ten population-based
cohort studies in seven European countries as listed below.
Data from 163,517 individuals were available from the
following cohort studies: Estonia: the population-based bio-
bank of the Estonian Genome Project of University of Tartu
(EGCUT) (n = 8,930) [32]; Finland: FINRISK2007 (DIL-
GOM) (n = 3,685) [33] and Health2000 (H2000) (n = 6,022)
[34]; Germany: the Cooperative Health Research in the
Region of Augsburg (KORA) study (n = 2,987) [35], Italy:
Collaborative Health Research in South Tyrol Study
(CHRIS) (n = 1,117) and the MICROS study (n = 1,060)
[36]; the Netherlands: LifeLines (n = 63,995) [37], and the
Prevention of REnal and Vascular ENd stage Disease study
(PREVEND) (n = 7,216) [38]; Norway: the Nord-Trøndelag
health study (HUNT2 survey) (n = 61,199) [39]; and United
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cohort (NCDS), also known as the 1958 birth cohort
(n = 7,306) [40]. A brief description of all participating
studies is given in the Additional file 1: Study descrip-
tions and methodologies.
All study participants were of European origin, aged
between 18 and 80 years, and had participated in a clin-
ical examination for anthropometric and blood pressure
measurements. Blood samples were taken for analysis of
lipids and glucose (Additional file 1: Study descriptions
and methodologies). Participants were only included if
all data on clinical and metabolic measurements needed
to define the status of MetS and obesity were available,.
All cohorts had gained approval through their local re-
search ethics committees or institutional review board
for secondary usage of data. Participants gave their
written informed consent to their study of origin. The
current study protocol also gained approval under the
data access and ethics governance requirements of the
study of origin. The data on the outcomes measured in
this study have not been published before by the individ-
ual cohorts.
Data harmonization process
Characteristics describing each cohort study (e.g. design,
sample size) are catalogued in a systematic way on the
BioSHaRE website (www.bioshare.eu). BioSHaRE investi-
gators met at a workshop in order to define the set of vari-
ables to be generated from the harmonization process.
These ‘target’ variables determine the data information
content that is required from each study to generate
compatible (i.e. harmonized) variables. By evaluating
study-specific questionnaires, standard operating proce-
dures and data dictionaries, used by the participating
cohort studies, the potential for each cohort study to
generate the target variables was determined. Then re-
searchers working with the data transformed their data
locally into a common harmonized format. Parts of this
process have been published recently [31], and details
related to pairing decisions taken and processing algo-
rithms are available online (https://www.bioshare.eu/
content/healthy-obese-project-dataschema).
Classification of obesity, metabolic syndrome and the
MHO phenotype
The criteria applied for measures of weight and height
required that each cohort study measured participants
when dressed in lightweight clothing and no shoes. Body
mass index (BMI) was calculated as weight in kilograms
divided by height in meters squared. Obesity was defined
according to the current World Health Organization
(WHO) classification as having a BMI ≥ 30 kg/m2 [41].
Four clinical measures were used to define the MetS
phenotype in the obese subjects based on the originalNCEP ATP III definition [42]: 1) elevated blood pressure,
defined as systolic blood pressure (SBP) ≥130 mmHg or
diastolic blood pressure (DBP) ≥85 mmHg, or antihyper-
tensive drug treatment; 2) elevated fasting blood glucose
level ≥6.1 mmol/l or use of blood glucose lowering agents
or history/diagnosis of type 2 diabetes; 3) decreased HDL-
cholesterol level (<1.03 mmol/l in men or <1.30 mmol/l in
women) or drug treatment aimed to increase HDL-
cholesterol; and 4) hypertriglyceridaemia (triglyceride
level ≥ 1.70 mmol/l) or drug treatment for elevated triglyc-
erides (Table 1). Data on waist circumference was not
available in all cohorts. However, > 95% of LifeLines par-
ticipants with obesity had increased waist circumference
according to the NCEP ATP III definition [42], and we
therefore considered the presence of ≥ 2 of the four clin-
ical measures as diagnostic for MetS [15]. In addition, we
also applied a set of less strict criteria in which the cut-off
levels for elevated systolic and diastolic blood pressure
were set at ≥140 mmHg and ≥90 mmHg, respectively, and
the cut-off level for elevated fasting blood glucose was set
at 7.0 mmol/l. As the components of MetS can be influ-
enced by smoking, we recorded whether the participants
were current smokers.
The methodology for measurement of the laboratory var-
iables in the various studies is described in the Additional
file 1. As not all participating cohorts had performed meas-
urement of triglycerides in fasting serum samples, we cor-
rected, as part of the harmonization process, non-fasting
triglycerides values based on the findings of a recent report
on the associations between fasting time and serum tri-
glycerides levels (i.e. the threshold of 2.1 mmol/l was
used) [43]. For the same reason, we used a different cut-
off value for non-fasting blood glucose (i.e. thresholds of
7.0 mmol/l and 7.8 mmol/l for ‘strict’ and ‘less strict’ cri-
teria were used, respectively (Table 1)). In the NCDS
study, fasting blood glucose was calculated from HbA1c
based on a regression formula obtained in the LifeLines
Cohort Study (see Additional file 1).
We collected and analysed three types of information:
(1) the presence of individual components of MetS in
obese participants in each cohort study; (2) the number
and percentage of MetS criteria fulfilled in obese partici-
pants in each cohort; and (3) the number and percentage
of subjects fulfilling the criteria for being metabolically
healthy obese in different age groups. MHO was estab-
lished when subjects with obesity had none of the MetS
components, and had no previous diagnosis of cardiovas-
cular disease. As there were age differences between the
cohorts, we performed age standardization against the
European population, as defined by the EU-27 Member
States population on January 1, 2010 (http://epp.eurostat.
ec.europa.eu/portal/page/portal/statistics/search_database,
accessed October 17, 2013). Prevalence was calculated for
men and women separately based on 10-year age groups.
Table 1 Criteria and the thresholds used for the definition of metabolically healthy obese individuals in each
cohort study
Strict criteria Less strict criteria
Blood pressure SBP≥ 130 mmHg or DBP ≥ 85 mmHg or
use of antihypertensive medication
SBP≥ 140 mmHg or DBP ≥ 90 mmHg
or use of antihypertensive medication
Elevated blood glucose fasting blood glucose≥ 6.1 mmol/l or non-fasting
blood glucose≥ 7.0 mmol/l or use of blood glucose
lowering medication or diagnosis of type 2 diabetes
fasting blood glucose≥ 7.0 mmol/l or non-fasting
blood glucose≥ 7.8 mmol/l or use of blood glucose
lowering medication or diagnosis of type 2 diabetes
Decreased HDL-cholesterol < 1.03 mmol/l in men or < 1.30 mmol/l in
women or medical treatment for low HDL
< 1.03 mmol/l in men or < 1.30 mmol/l
in women or medical treatment for low HDL
Elevated triglycerides* ≥ 1.70 mmol/l or medication for elevated triglycerides ≥ 1.70 mmol/l or medication
for elevated triglycerides
Diagnosis for CVD Yes Yes
Abbreviations: CVD cardiovascular disease, DBP diastolic blood pressure, SBP systolic blood pressure.
The presence of ≥ 2 abnormal clinical measures (blood pressure, blood glucose, HDL-cholesterol, triglycerides) according to the strict criteria was considered
diagnostic for MetS.
Metabolically healthy obesity is defined as having BMI ≥ 30, none of the following criteria of the metabolic syndrome [15,42], and no cardiovascular disease.
*In case of non-fasting measurements, the cut-off value was set at 2.10 mmol/l.
van Vliet-Ostaptchouk et al. BMC Endocrine Disorders 2014, 14:9 Page 4 of 13
http://www.biomedcentral.com/1472-6823/14/9The definition of prevalent cardiovascular disease varied
slightly between cohorts (Additional file 1: The definition
of cardiovascular disease), but in the majority of cohort
studies, it was based on self-reported history of acute myo-
cardial infarction, stroke, angina pectoris or cardiovascular
intervention (CABG or PTCA).
Statistical analyses
Results are presented as means ± standard deviation, or
number and percentage. Frequency of individual compo-
nents of MetS were calculated, both for the whole popula-
tion of obese individuals and for specific age categories. If
needed, data are given for men and women separately. As
this is a descriptive observational study, no formal statis-
tical testing was performed.Results
Overall, data for 163,517 individuals were available for
the analysis, of whom 28,077 (17.2%) were obese (11,465
(15.8%) men and 16,612 (18.3%) women). Table 2 sum-
marizes the clinical characteristics of obese participants
from each cohort study. Mean age of the obese partici-
pants varied from 44.0 to 59.6 years. In all cohorts, the
frequency of obesity was greater among women than
among men (only statistically significant (P < 0.05) for
Health2000, LifeLines, Prevend and HUNT2), while it
was greater among men in the NCDS cohort (P = 0.033).
The highest prevalence of obesity was found in Germany
(26.3%, mean age of the participants 59.6 years), Finland
(DILGOM cohort, 25.7%, 57.3 years), Estonia (23%,
52.6 years), and the United Kingdom (22.9%, 44.0 years),
while the lowest prevalence of obesity was observed in
the Italian studies CHRIS (11.6%, 53.6 years) and
MICROS (14.8%, 54.9 years) (Figure 1). The percentage
of individuals currently smoking varied between 15 and
31% (Table 2).The observed prevalence of MetS was mainly driven
by the presence of elevated blood pressure with a range
from 60% to 85% of individuals fulfilling the criterion for
high BP (Table 3, Figure 2). In contrast, elevated blood
glucose contributed least to MetS, although we did ob-
serve considerable diversity between the cohorts. The
percentage of obese individuals with elevated blood glu-
cose varied from 7% in the UK NCDS cohort to 52% in
the Finnish DILGOM cohort. A similar difference was
observed in the percentage of the obese individuals with
decreased HDL-cholesterol level: the lowest prevalence
was observed in the Italian studies (9% and 13% in the
MICROS and CHRIS cohorts, respectively), while the
highest prevalence was detected in the Dutch PREVEND
cohort (57%). The percentage of the individuals with ele-
vated triglyceride levels ranged between 31% in the
Dutch LifeLines study and 55% in the UK NCDS partici-
pants. As a result, the age-standardized percentage of
men with MetS according to the classic 2001 NCEP
ATP III criteria ranged from 42.7% in the Italian CHRIS
cohort to 78.2% in the Finnish DILGOM cohort, and for
women from 24% in CHRIS to 64.8% in the Finnish
Health2000 cohort (Figure 3A,B).
As expected, when less strict MetS criteria were
used, the percentage of obese individuals with elevated
blood pressure or blood glucose was lower (Table 3).
This also resulted in a lower number of subjects with
MetS (Table 4A,B).
Across all ten cohorts, a total of 3,387 obese partici-
pants (12%) did not have any metabolic abnormalities
according to the strict definition of MetS, as well as no
previous diagnosis of cardiovascular disease, as defined
by the MHO phenotype. After age standardization, the
highest prevalence of MHO in men was found in the
Italian CHRIS study (19%) and in the German KORA
study (13.5%), and in women in UK NCDS (28.4%),
Dutch LifeLines (23.1%), KORA (21.8%) and CHRIS
Table 2 Characteristics of the obese (BMI ≥ 30) participants
Country & study Estonia Finland Germany Italy The Netherlands Norway UK
EGCUT DILGOM HeaIth2000 KORA CHRIS MICROS LifeLines PREVEND HUNT2 NCDS
Total number of participants (N) 8,930 3,685 6,022 2,987 1,117 1,060 63,995 7,216 61,199 7,306
Number with BMI≥ 30 (%) 2,053 (23.0) 946 (25.7) 1,342 (22.3) 786 (26.3) 130 (11.6) 157 (14.8) 9,934 (15.5) 1,137 (15.8) 9,922 (16.2) 1,670 (22.9)
Gender (M (%)/F) 698 (34.0)/1,355 399 (42.2)/547 573 (42.7)/769 373 (47.5)/413 60 (46.2)/70 57 (36.3)/100 3,813 (38.4)/6,121 514 (45.2)/623 4,104 (41.4)/5,818 874 (52.3)/796
Age (yrs) 52.6 ± 14.1 57.3 ± 11.6 54.5 ± 12.8 59.6 ± 12.0 53.6 ± 12.9 54.9 ± 15.2 47.4 ± 11.7 53.5 ± 11.7 53.5 ± 15.4 44.0 ± 0
BMI (kg/m2) 34.4 ± 4.1 34.2 ± 4.1 33.6 ± 3.4 33.8 ± 3.7 33.1 ± 3.4 33.6 ± 4.5 33.6 ± 3.6 33.2 ± 3.3 33.2 ± 3.1 33.9 ± 3.8
Waist circumference (cm) 107 ± 12 110 ± 11 108 ± 10 109 ± 11 NA NA 108 ± 10 105 ± 11 101 ± 10 106 ± 10
HDL cholesterol (mmol/l) 1.52 ± 0.33 1.30 ± 0.33 1.17 ± 0.32 1.31 ± 0.31 1.54 ± 0.45 1.54 ± 0.34 1.28 ± 0.33 1.16 ± 0.34 1.24 ± 0.35 1.38 ± 0.32
Men 1.35 ± 0.28 1.15 ± 0.26 1.05 ± 0.27 1.21 ± 0.29 1.31 ± 0.32 1.36 ± 0.25 1.13 ± 0.26 1.01 ± 0.27 1.10 ± 0.29 1.30 ± 0.30
Women 1.60 ± 0.32 1.42 ± 0.33 1.26 ± 0.32 1.40 ± 0.30 1.74 ± 0.45 1.65 ± 0.34 1.38 ± 0.33 1.29 ± 0.33 1.35 ± 0.36 1.47 ± 0.31
Triglycerides (mmol/I) 2.10 ± 1.16 1.82 ± 1.01 2.02 ± 1.22 1.77 ± 1.09 1.53 ± 0.99 1.87 ± 1.27 1.54 ± 1.02 1.88 ± 1.33 2.35 ± 1.39 2.17 ± 1.63
Blood glucose (mmol/I) 4.8 ± 1.8 6.4 ± 1.3 5.9 ± 1.7 5.9 ± 1.2 5.6 ± 0.9 5.4 ± 1.5 5.4 ± 1.3 5.4 ± 1.6 5.9 ± 2.0 4.9 ± 1.1
Systolic blood pressure (mmHg) 136 ± 17 140 ± 19 142 ± 20 128 ± 18 128 ± 14 143 ± 22 133 ± 15 139 ± 20 146 ± 22 132 ± 16
Diastolic blood pressure (mmHg) 84 ± 11 83 ± 11 87 ± 10 78 ± 10 83 ± 8 85 ± 11 77 ± 9 77 ± 10 85 ± 13 83 ± 10
Current smoking (%) 30.5 15.3 23.0 17.7 15.4 28.0 19.9 26.3 30.8 23.9
Number with MetS (M/F) 410/606 323/355 425/515 229/216 26/26 34/33 2,208/2,262 346/335 2,792/3,114 513/269
Number with MHO (M/F) 34/166 7/37 19/43 34/61 11/12 4/9 359/1,433 26/94 180/553 79/226
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Figure 1 The prevalence of obesity in the participating cohorts given as a percentage of the total sample size of the cohort.
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Finnish cohorts (2.3 and 3.6% for men, 7.3 and 12.3% for
women) and the Norwegian HUNT2 study (5.9% in
men, 14% in women) (Figure 3A,B).
The trend towards a higher percentage of MHO in
women compared with men was evident in almost all
studies. This sex difference was most apparent in the
NCDS cohort, in which 28.4% of obese women were
metabolically healthy in comparison with only 9% of
obese men with the same phenotype (Figure 3). In con-
trast, the percentage of men and women with MHO
was similar in the Italian CHRIS study (19% versus
21.1%). These findings were also independent of theTable 3 The frequency of individual components of the meta
Estonia Finland Germany
EGCUT DILGOM Health2000 KORA
Total N 2,053 946 1,342 786
Metabolic component
Strict criterium for
high BP (%)
1,637 (79.7) 801 (84.7) 1,104 (82.3) 573 (72.9)
Strict criterium for
blood glucose (%)
482 (23.4) 493 (52.1) 329 (24.5) 251 (31.9)
Criterium for HDL
cholesterol (%)
273 (13.3) 346 (36.6) 750 (55.9) 281 (35.8)
Criterium for
triglycerides (%)
815 (39.7) 407 (43.0) 710 (52.9) 317 (40.3)
Less strict criterium
for high BP (%)
1,386 (67.5) 670 (70.8) 916 (68.3) 498 (63.4)
Less strict criterium
for blood glucose (%)
463 (22.5) 176 (18.6) 148 (11.0) 135 (17.2)definition of MHO, as we observed the same tendency
with both strict and less strict criteria (data not
shown).
Overall, we observed a decrease in the prevalence of
MHO with increasing age, independent of sex and the
MetS definition criteria used (Figure 4A,B). This pattern
was seen in all cohorts except the Italian CHRIS study,
in which the prevalence of MHO appeared to be rela-
tively constant until the age of 60. In all cohorts, a sub-
set of the obese individuals remained metabolically
healthy, even in the oldest age group (≥ 60 years). The
highest prevalence of MHO among those 60 years and
older was observed in the Dutch LifeLines study (8%).bolic syndrome in obese (BMI ≥ 30) individuals
Italy The Netherlands Norway UK
CHRIS MICROS LifeLines PREVEND HUNT2 NCDS
130 157 9,934 1,137 9,922 1,669
83 (63.9) 123 (78.3) 6,407 (64.5) 825 (72.6) 7,991 (80.5) 998 (59.8)
27 (20.8) 25 (15.9) 1,524 (15.3) 161 (14.2) 1,377 (13.9) 114 (6.8)
17 (13.1) 14 (8.9) 3,913 (39.4) 646 (56.8) 4,547 (45.8) 387 (23.2)
44 (33.9) 68 (43.3) 3,028 (30.5) 496 (43.6) 4,693 (47.3) 912 (54.6)
64 (49.2) 98 (62.4) 4,492 (45.2) 660 (58.2) 6,447 (65.0) 609 (36.5)
12 (9.2) 12 (7.6) 825 (8.3) 87 (7.7) 920 (9.3) 92 (5.5)
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Figure 2 The frequency of individual components of the metabolic syndrome among obese subjects (BMI ≥ 30 kg/m2). The presence of
the metabolic syndrome mainly depends on the presence of a high blood pressure followed by the level of triglycerides and HDL cholesterol
and – to a lesser extent – blood glucose levels. BP = blood pressure, BG = blood glucose, HDL-C = high density lipoprotein cholesterol,
TG = triglycerides. *Denotes non-fasting measurement of blood glucose.
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In this large-scale collaborative study, we evaluated the
prevalence of metabolic syndrome and healthy obesity
among obese individuals using the data of 163,517 people
from ten European cohort studies from seven different
countries. We found considerable variation in the preva-
lence of both phenotypes suggesting that the distribution
of the MetS and MHO across the different populations in
general is not equal. However, our analysis did reveal a
consistently higher prevalence of the MHO phenotype in
women compared to men. Furthermore, the percentage of
obese subjects with a favourable risk profile decreases with
increasing age in all cohorts.0
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Figure 3 Age-standardized prevalence of metabolic syndrome (MetS)
(BMI ≥ 30 kg/m2) individuals in the participating cohorts, separately sWith the exception of the Italian, Norwegian and UK
cohorts, the prevalence of obesity was much higher in the
European populations we studied than was reported in the
most recent review addressing the distribution of obesity
in Europe [2]. Such differences may be due to potential
underestimation of the prevalence of obesity in the sys-
tematic review because of the inclusion of studies using
self-reported BMI [2]. In our study, the data on BMI were
obtained through direct measurements made by trained
research nurses or study assistants which provides more
accurate estimation of obesity prevalence in the participat-
ing cohorts. Another explanation for the discrepancy in
the prevalence patterns may be related to the difference in0
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%
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B
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and metabolically healthy obesity (MHO) amongst obese
hown for men (panel A, left) and women (panel B, right).
Table 4 Number of components of the metabolic syndrome (waist circumference not included) present among obese participants
A. Number of MetS component (strict criteria) Estonia Finland Germany Italy The Netherlands Norway UK
EGCUT DILGOM Health2000 KORA CHRIS MICROS Lifelines PREVEND HUNT2 NCDS
Total N 2,053 946 1,342 786 130 157 9,934 1,137 9,922 1,669
0 criteria present (%) 242 (11.8) 46 (4.9) 76 (5.7) 98 (12.5) 38 (29.2) 18 (11.5) 1,808 (18.2) 120 (10.6) 755 (7.6) 305 (18.3)
1 criterium present (%) 793 (38.6) 222 (23.5) 326 (24.3) 243 (31.0) 40 (30.8) 72 (45.9) 3,656 (36.8) 336 (29.6) 3,261 (32.9) 582 (34.9)
2 criteria present (%) 689 (33.6) 309 (32.7) 400 (29.8) 227 (28.9) 31 (23.9) 45 (28.7) 2,604 (26.2) 323 (28.4) 2,916 (29.4) 565 (33.9)
3 criteria present (%) 270 (13.2) 269 (28.4) 393 (29.3) 147 (18.7) 15 (11.5) 20 (12.7) 1,456 (14.7) 286 (25.2) 2,445(24.6) 169 (10.1)
4 criteria present (%) 59 (2.9) 100 (10.6) 147 (11.0) 71 (9.0) 6 (4.6) 2 (1.3) 410 (4.1) 72 (6.3) 545 (5.5) 48 (2.9)
B. Number of MetS components (less strict criteria) Estonia Finland Germany Italy The Netherlands Norway UK
EGCUT DILGOM Health2000 KORA CHRIS MICROS LifeLines PREVEND HUNT2 NCDS
Total N 2,053 946 1,342 786 130 157 9,934 1,137 9,922 1,669
0 criteria present (%) 381 (18.6) 112 (11.8) 134 (10.0) 140 (17.8) 53 (40.8) 29 (18.5) 2,767 (27.9) 172 (15.1) 1,335 (13.5) 452 (27.1)
1 criterium present (%) 778 (37.9) 319 (33.7) 375 (27.9) 260 (33.1) 35 (26.9) 77 (49.0) 3,582 (36.1) 344 (30.3) 3,304 (33.3) 613 (36.7)
2 criteria present (%) 619 (30.2) 307 (32.5) 426 (31.7) 221 (28.1) 27 (20.8) 39 (24.8) 2,290 (23.1) 355 (31.2) 2,901 (29.2) 456 (27.3)
3 criteria present (%) 227 (11.1) 166 (17.6) 331 (24.7) 131 (16.7) 12 (9.2) 11 (7.0) 1,084 (10.9) 229 (20.1) 2,027 (20.4) 117 (7.0)
4 criteria present (%) 48 (2.3) 42 (4.4) 76 (5.7) 34 (4.3) 3 (2.3) 1 (0.6) 211 (2.1) 37 (3.3) 355 (3.6) 31 (1.9)
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Figure 4 Percentage of subjects (panel A: men; panel B: women) meeting the criteria of being ‘healthy obese’. The results are stratified
for different age groups. In general, within each cohort the prevalence of healthy obesity decreases with increasing age. Note that more females
are metabolically healthier than males.
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http://www.biomedcentral.com/1472-6823/14/9the time period when the studies were conducted. While
the surveys included in the systematic review were per-
formed between the mid-1980s and 2003, most of the data
in our study were collected after 2000, with the earliest
data available from 1995 and the most recent data from
2012. The differences in estimations of the obesity preva-
lence can, therefore, present different phases of an increas-
ing trend. Although our data are obtained from large
population-based cohort studies or biobanks, we have torealize that our results cannot always be generalized to the
overall prevalence in the specific countries, as some cohorts
have only collected data from a specific region of that coun-
try (CHRIS/MICROS/HUNT2), or from a specific age
group (NCDS). Despite the detected variation, the data
confirm the observations that obesity in European countries
continued to rise the last decade and has reached epidemic
proportions [2]. However, recent publications suggest level-
ling off of the obesity epidemic [44-46], although in subjects
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lence still is observed [47].
The Finnish cohorts had the highest prevalence of MetS
among obese subjects and the lowest percentage of MHO.
In contrast, in the Italian MICROS and the Dutch LifeLines
studies we observed a lower prevalence of MetS among
obese subjects together with a higher percentage of MHO.
Similar patterns in the occurrence of MetS in Europe have
been reported previously [48]. MetS is a constellation of
metabolic risk factors, associated with an increased risk for
the development of atherosclerotic cardiovascular disease
as well as type 2 diabetes mellitus [15,16,49]. MetS has
been shown to be the major risk determinant of heart
disease, also when a population generally has low levels
of HDL- and LDL-cholesterol [50]. The most frequent
MetS component present in obese individuals was ele-
vated blood pressure. In the 10 studies, obesity coincided
with hypertension in 60% to 85% cases. In contrast, we ob-
served considerable variations in the prevalence of other
components of MetS, especially blood glucose and HDL-
cholesterol. A blood pressure exceeding the strict criterion
for a high blood pressure can be accounted as a main
contributor promoting unhealthy obesity and metabolic
syndrome in the Finnish cohorts in this study. Finnish ten-
dency for elevated blood pressure has also been detected
earlier, recently by The European Heart Network and The
European Society of Cardiology [51].
Our study extends previous efforts to describe the
phenomenon of healthy obesity and to estimate its
prevalence in different countries in several important
ways, including helping to disentangle whether differ-
ences in the prevalence of MHO are due to geographic
variation or differences in measurements. Using a large
amount of validated information, we applied a rigorous
protocol to harmonize data from multiple population-
based European studies, and ensure a high level of
homogeneity of the MetS definition used to calculate the
MHO prevalence. Recently, the lack of a standard ap-
proach to use the same sets of criteria and cut-off values
to define metabolic abnormalities has been highlighted
as the major source of the high variability in the re-
ported MHO prevalence [19,24,25]. Yet, our results also
demonstrate a significant diversity in the prevalence of
MHO across Europe using the harmonized criteria to
define MetS. The highest percentage of MHO in men
was found in CHRIS and KORA, and in women in
NCDS, LifeLines, KORA and CHRIS, whereas the low-
est prevalence was found in the Finnish cohorts and in
HUNT2. In our study, we have used the established risk
factors associated with the metabolic syndrome [41,42]
to identify the MHO phenotype. Our data on MetS
components is consistent with the outcome of previ-
ously performed studies on the prevalence of the meta-
bolic abnormalities in Europe [48,52]. As age and sexare important factors in the development of MetS, we
have also evaluated the age- and sex-stratified preva-
lence of MHO per decade. Our results indicate a higher
prevalence of the MHO phenotype in women than in
men as well as an age-related decline in the percentage
of obese subjects with a metabolically healthy phenotype
[19,24]. Collectively, our findings raise additional ques-
tions about the underlying factors promoting the variation
in the prevalence of MHO across different populations.
Such variation in the distribution of metabolic phenotypes
can be explained by several factors, including difference in
age of the cohort participants, differences in environmen-
tal factors such as physical activity level, diet, smoking and
alcohol use, and differences in the selection and inclusion
of participants [52]. Also the psychosocial profile and gen-
etic factors [19,24] may play a role. While behavioral fac-
tors, i.e. higher levels of physical activity or moderate
alcohol intake, have been shown to be associated with the
MHO phenotype [18], there is no evidence yet whether
genetic background and divergence between populations
does contribute to the metabolically favorable profile in
obesity [24].
Given the number of serious health problems associated
with obesity including type 2 diabetes, cardiovascular dis-
ease, and an increased risk for various types of cancer, the
investigation of the healthy obesity phenotype may provide
novel insights into the pathophysiology of obesity-related
co-morbidities and help to identify at-risk obese individ-
uals. Furthermore, it may help in the development of bet-
ter interventions for obese patients. There are strong
indications that weight loss may not have a beneficial ef-
fect on certain metabolic risk factors in MHO individuals
[20] and even result in a paradoxical response [53]. There-
fore, the one-size-fits-all approach regarding the conse-
quences of obesity should be revisited, and the prevailing
concept in the health care system that obesity is always
bad should be re-evaluated. Also, a proper classification of
the at-risk and metabolically benign obese individuals
should be taken into account in medical research to pre-
vent any bias in the interpretation of the results.
The main strengths of this descriptive study are the
large sample size and the application of harmonized cri-
teria to evaluate the prevalence of MetS and the degree
of the MHO across different European cohort studies.
Through our harmonization process [31], we have shown
the possibility for collaborative research based on a careful
harmonization process across multiple participating cohort
studies. Several important factors may have a bearing on
the results. First, we used BMI to define the obesity status.
Since BMI is a measure of general obesity and cannot dis-
tinguish between fat and lean mass, other measures such as
waist circumference (WC) or waist-hip-ratio (WHR) might
be better indicators of visceral fat accumulation. Although
a few studies reported lower fat accumulation in MHO
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normalities [17,24], no difference in the prevalence of
MHO was found when WC was used instead of BMI to
define the MHO phenotype in the NHANES cohort
[18]. Second, although our harmonized measures cap-
tured the essential information content for the MHO
phenotype, there were differences between studies in
the way that specific variables such as blood pressure
and serum lipid levels were measured. Also, our cut-off
values for non-fasting measurements of, for example,
blood glucose may underestimate the actual degree of
the MHO present in the corresponding studies. Third,
although many participating cohort studies included
several thousands of participants, their health and life-
style habits may not always be representative of the gen-
eral population in this specific country because of bias
in participation or differences in recruitment of partici-
pants. We also cannot exclude that a potential partici-
pation bias could affect the results [54]. As such, higher
participation rates from either healthy or unhealthy in-
dividuals can influence the outcome, and it cannot be
ruled out that the high percentage of MHO in the Life-
Lines Cohort Study may – at least in part – be explained
by a preponderance of healthy individuals willing to
participate.
An important factor to discuss is the time period in
which the initial screening of each individual cohort was
performed. Data in some cohorts were collected in the
1990s, while, for example, the participants in the Dutch
LifeLines Cohort Study were recruited between 2007 and
2012, and in the Italian CHRIS study after August 2011.
There have been several changes in environmental factors
such as health behaviour and smoking pattern over time,
which may have a bearing on the prevalence of MetS and
on health in general. In many countries higher awareness
of the importance of increased physical activity [55] or
smoking cessation [56,57] have been recognized, although
it appears that the current epidemic of obesity is still on-
going [2]. As an example, cessation of smoking is on one
hand associated with weight gain [58], which may be per-
ceived negatively by individuals [59], but it also results in
improvement of the metabolic profile as smoking cessa-
tion is accompanied by an increase of HDL cholesterol
and reduction of triglycerides [60]. It is important to
note that the major objective of this descriptive study
was to evaluate the phenomenon of healthy obesity
among the participating European population-based
studies. The BioSHaRE-HOP consortium is currently
expanding its harmonization efforts, and assessing dif-
ferences in lifestyle factors such as nutritional habits,
physical activity, smoking and general awareness of
health between the various participating countries in
order to have a better estimate of the characterization
and the determinants of (healthy) obesity.Conclusion
In summary, we report the first scientific results of this col-
laborative project on the prevalence of healthy obesity
within a FP7 funded consortium, BioSHaRE-EU. We have
co-analysed data across the participating studies by apply-
ing careful harmonization algorithms. The present findings
indicate considerable variation in the occurrence of MHO
across the different European populations even when uni-
fied criteria or definitions were used to classify this pheno-
type. Further studies are needed to identify the underlying
factors for these differences. This area of research will im-
prove our understanding of obesity in general and possibly
identify novel preventive measures for the consequences
of obesity.
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